Isis Pharmaceuticals, Inc.

Regulus Therapeutics Inc.

Erich Koller

Kenneth W Dobie

C Frank Bennett

Ravi Jain

Susan M Freier

Eric E Swayze

Richard Holmes Griffey

Balkrishen Bhat

Brenda F Baker

Eric G Marcusson

Timothy A Vickers

Christine Esau

Bridget Lollo

Eigen Peralta

Nicholas M Dean

The present invention provides method of optimizing the efficacy and potency of antisense drugs. In certain embodiments, the invention provides assays useful for determining favorable oligonucleotide characteristics and excipients for improved cellular uptake.

Compounds and methods for improving cellular uptake of oligomeric compounds

Antisense compounds, compositions and methods are provided for modulating the expression of kinesin-like 1. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding kinesin-like 1. Methods of using these compounds for modulation of kinesin-like 1 expression and for treatment of diseases associated with expression of kinesin-like 1 are provided.

Antisense modulation of kinesin-like 1 expression

Compounds, compositions and methods are provided for modulating the expression and function of small non-coding RNAs. The compositions comprise oligomeric compounds, targeted to small non-coding RNAs. Methods of using these compounds for modulation of small non-coding RNAs as well as downstream targets of these RNAs and for diagnosis and treatment of disease associated with small non-coding RNAs are also provided.

Method of inhibiting miR-33 using a modified oligonucleotide

The present invention provides method of optimizing the efficacy and potency of antisense drugs. In certain embodiments, the invention provides assays useful for determining favorable oligonucleotide characteristics and excipeints for improved cellular uptake.

Oligomeric compounds and compositions for use in modulation of small non-coding RNAs

Compounds, compositions and methods are provided for modulating the expression of Aurora B. The compositions comprise oligonucleotides, targeted to nucleic acid encoding Aurora B. Methods of using these compounds for modulation of Aurora B expression and for diagnosis and treatment of diseases and conditions associated with expression of Aurora B are provided. Also provided are methods of using these compounds to modulate the growth of cancer cells, including p53-deficient cancer cells.

Modulation of Aurora B expression

Growing community of inventors

Carlsbad, CA, United States of America

Erich Koller